Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

References

• Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;2020:1.
   Google Scholar
• Kapoor N, Kalra S, Al Mahmeed W, et al. The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact. Diabetes Therapy. 2022;13(10):1723–1736. doi:10.1007/s13300-022-01311-2
   PubMed Web of Science ®Google Scholar
• Martín‐Calvo N, Goni L, Tur JA, Martínez JA. Low birth weight and small for gestational age are associated with complications of childhood and adolescence obesity: systematic review and meta‐analysis. Obes Rev. 2022;23:e13380. doi:10.1111/obr.13380
   PubMed Web of Science ®Google Scholar
• Tam BT, Morais JA, Santosa S. Obesity and ageing: two sides of the same coin. Obes Rev. 2020;21(4):e12991. doi:10.1111/obr.12991
   PubMed Web of Science ®Google Scholar
• Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021;131(1). doi:10.1172/JCI140065
   Web of Science ®Google Scholar
• Muennig P, Lubetkin E, Jia H, Franks P. Gender and the burden of disease attributable to obesity. Am J Public Health. 2006;96:1662–1668. doi:10.2105/AJPH.2005.068874
   PubMed Web of Science ®Google Scholar
• Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118:1752–1770. doi:10.1161/CIRCRESAHA.115.306883
   PubMed Web of Science ®Google Scholar
• Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;2014:587–591. doi:10.2147/DMSO.S67400
   Google Scholar
• De Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71:332–338. doi:10.1017/S0029665112000092
   PubMed Web of Science ®Google Scholar
• Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23:6365–6378. doi:10.1038/sj.onc.1207751
   PubMed Web of Science ®Google Scholar
• GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. doi:10.1056/NEJMoa1614362
   PubMed Web of Science ®Google Scholar
• Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3–21. doi:10.1111/j.1753-4887.2011.00456.x
   PubMed Web of Science ®Google Scholar
• Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–825. doi:10.1016/S0140-6736(11)60814-3
   PubMed Web of Science ®Google Scholar
• Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. doi:10.1016/j.jacc.2017.11.011
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. doi:10.1056/NEJMoa1212914
   PubMed Web of Science ®Google Scholar
• Elhayany A, Lustman A, Abel R, Attal‐Singer J, Vinker S. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1‐year prospective randomized intervention study. Diabetes Obes Metab. 2010;12(3):204–209. doi:10.1111/j.1463-1326.2009.01151.x
   PubMed Web of Science ®Google Scholar
• Hall KD, Kahan S. Maintenance of lost weight. Med Clin North Am. 2018;102:183–197. doi:10.1016/j.mcna.2017.08.012
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14:1–11. doi:10.1186/s12916-015-0545-7
   PubMed Web of Science ®Google Scholar
• Lin CH, Shao L, Zhang YM, et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother. 2020;21:275–285. doi:10.1080/14656566.2019.1695779
   PubMed Web of Science ®Google Scholar
• Kela R, Khunti K, Davies MJ. Liraglutide for type 2 diabetes mellitus. Expert Opin Biol Ther. 2011;11:951–959. doi:10.1517/14712598.2011.583641
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs. 2011;71:1675–1688. doi:10.2165/11592810-000000000-00000
   PubMed Web of Science ®Google Scholar
• Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335–1342. doi:10.2337/diacare.27.6.1335
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310–1319. doi:10.1038/ijo.2016.52
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443–1451. doi:10.1038/ijo.2013.120
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616. doi:10.1016/S0140-6736(09)61375-1
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734–739. doi:10.1111/dom.13125
   PubMed Web of Science ®Google Scholar
• Nikolic D, Patti AM, Giglio RV, et al. Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study. Diabetes Ther. 2022;13:453–464. doi:10.1007/s13300-022-01217-z
   PubMed Web of Science ®Google Scholar
• Ferrari F, Fierabracci P, Salvetti G, et al. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Invest. 2020;43:1779–1785. doi:10.1007/s40618-020-01334-1
   PubMed Web of Science ®Google Scholar
• Wharton S, Liu A, Pakseresht A, et al. Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity. 2019;27:917–924. doi:10.1002/oby.22462
   PubMed Web of Science ®Google Scholar
• Santini S, Vionnet N, Pasquier J, et al. Marked weight loss on liraglutide 3.0 mg: real-life experience of a Swiss cohort with obesity. Obesity. 2023;31:31. doi:10.1002/OBY.23596
   PubMed Web of Science ®Google Scholar
• Park JH, Kim JY, Choi JH, et al. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int J Obes. 2021;45:776–786. doi:10.1038/s41366-021-00739-z
   PubMed Web of Science ®Google Scholar
• Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR study. Int J Clin Pract. 2019;73. doi:10.1111/IJCP.13399
   Web of Science ®Google Scholar
• Gallo M. Thyroid safety in patients treated with liraglutide. J Endocrinol Invest. 2013;36:140–145. doi:10.1007/BF03346749
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486. doi:10.1210/en.2009-1272
   PubMed Web of Science ®Google Scholar
• Elsayed NA, Aleppo G, Aroda VR, et al. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46:S140–57. doi:10.2337/dc23-S009
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly Glucagon-Like Peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370–7380. doi:10.1021/acs.jmedchem.5b00726
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Jensterle M, Rizzo M, Janež A. Semaglutide in obesity: unmet needs in men. Diabetes Ther. 2023;14:461–465. doi:10.1007/s13300-022-01360-7
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, Phase 3 trial. Lancet. 2021;397:971–984. doi:10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–1413. doi:10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–1425. doi:10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–2091. doi:10.1038/s41591-022-02026-4
   PubMed Web of Science ®Google Scholar
• Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–69. doi:10.1016/j.ahj.2020.07.008
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138–150. doi:10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12:143. doi:10.1007/s13300-020-00981-0
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:623–633. doi:10.1016/S2213-8587(22)00188-7
   PubMed Web of Science ®Google Scholar
• Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: a network meta‐analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543. doi:10.1111/obr.13543
   PubMed Web of Science ®Google Scholar
• Muzurović EM, Volčanšek Š, Tomšić KZ, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146371. doi:10.1177/10742484221146371
   Web of Science ®Google Scholar
• Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacother J Hum Pharmacol Drug Ther. 2000;20:270–279. doi:10.1592/phco.20.4.270.34882
   Google Scholar
• Drew BS, Dixon AF, Dixon JB, Drew andrew F, Dixon John B, Dixon BS. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3:817–821.
   PubMedGoogle Scholar
• Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–172. doi:10.1016/S0140-6736(97)11509-4
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sj¨ostr¨om L, Sj¨ostr S, Sj¨ostr¨om S XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients; 2004. Available from: http://diabetesjournals.org/care/article-pdf/27/1/155/563509/zdc00104000155.pdf. Accessed February 9, 2023.
   Google Scholar
• Ballinger A. Orlistat in the treatment of obesity. Expert Opin Pharmacother. 2005;1:841–847. doi:10.1517/1465656614841
   Google Scholar
• Ardissino M, Vincent M, Hines O, et al. Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2022;8:179–186. doi:10.1093/ehjcvp/pvaa133
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol. 2011;9:647–657. doi:10.2174/157016111797484080
   PubMed Web of Science ®Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7:796. doi:10.5114/aoms.2011.25554
   PubMed Web of Science ®Google Scholar
• Smith SM, Meyer M, Trinkley KE. Phentermine/Topiramate for the treatment of obesity new drug approvals. Ann Pharmacother I. 2013;47. doi:10.1345/aph.1R501
   Google Scholar
• Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11:556–562. doi:10.1038/oby.2003.78
   PubMedGoogle Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20:330–342. doi:10.1038/oby.2011.330
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults. Obesity. 2013;21(11):2163–2171. doi:10.1002/oby.20584
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352. doi:10.1016/S0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308. doi:10.3945/ajcn.111.024927
   PubMed Web of Science ®Google Scholar
• Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity. 2021;29:985–994. doi:10.1002/oby.23152
   PubMed Web of Science ®Google Scholar
• Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;1419–1427. doi:10.2147/DDDT.S55587
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605. doi:10.1016/S0140-6736(10)60888-4
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–120. doi:10.1038/oby.2010.147
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935–943. doi:10.1002/oby.20309
   PubMed Web of Science ®Google Scholar
• Sharfstein JM, Psaty BM. Evaluation of the cardiovascular risk of naltrexone-bupropion: a study interrupted. JAMA. 2016;315:984–986. doi:10.1001/jama.2016.1461
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990–1004. doi:10.1001/jama.2016.1558
   PubMed Web of Science ®Google Scholar